The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Michael F. Press
No relevant relationships to disclose
Peter H. O'Donnell
Honoraria - Dendreon (B)
Elizabeth R. Plimack
Research Funding - Dendreon
Other Remuneration - Dendreon
Jean H. Hoffman-Censits
No relevant relationships to disclose
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius ; Genentech; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Helsinn Therapeutics; Jounce Therapeutics; MedImmune
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Melissa Chen
No relevant relationships to disclose
Michael Locker
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Dean F. Bajorin
Consultant or Advisory Role - Dendreon; Lilly; Pfizer
Honoraria - Lilly
Research Funding - Amgen; Dendreon; Genentech; Novartis; Pfizer